UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-13

The investigation of CD49d is also taking place with cancer treatments. With CD49d+ (over express) patients having a far less overall survival rate at 5 and 10yrs when compared with CD49d- patients with CLL. This is now being tested with other blood cancer types. Where as CD49f+ patients have a lesser survival rate than CD49f- patients with solid tunor type cancers.
Inflammation driven by CD49d over expression, is also being linked to how smoking can cause lung cancer.
It would seem that the bodies T cell response is linked to CD49d and CD49f, which act like a homing agent. Over expression of CD49, however, reacts adversely to the T cell effectiveness.

Inflammation is really one of the greatest route causes of most ailments. The body uses Inflammation to fight off the bad guys and heal itself. But when this chemistry goes wrong, it can lead to some very serious complications. A safe and well tolerated treatment for Inflammation has huge potential in Many varied feilds.

DMD is only the beginning if this trial goes well.